CPT-11 (irinotecan), a DNA topoisomerase I inhibitor is one of the main treatments for
colorectal cancer. The main dose limiting toxicities are neutropenia and late onset diarrhea …

Chemotherapy-induced diarrhoea : Current Opinion in Supportive and Palliative Care
Chemotherapy-induced diarrhoea : Current Opinion in Supportive and Palliative Care Log in or …

As the primary enzyme responsible for the activatable conversion of Irinotecan (CPT-11) to
SN-38, carboxylesterase 2 (CES2) is a significant predictive biomarker toward CPT-11 …

Irinotecan (also known as CPT-11) is a topoisomerase I inhibitor first approved for clinical
use as an anticancer agent in 1996. Over the past more than two decades, it has been …

Objective: Symptomatic therapy is an intervention centered entirely on symptom
management and pain relief. The utilization of charcoal in diarrhea management is a …

Background We performed a prospective study to evaluate the efficacy of activated charcoal
(AC) to prevent irinotecan‐induced diarrhea (IID). Procedure We designed a prospective …

One of the dose‑limiting toxicities of irinotecan hydrochloride (CPT‑11) is delayed‑onset
diarrhea. CPT‑11 is converted to its active metabolite, SN‑38, which is conjugated to SN‑38 …

Amongst several drug delivery schemes for perfect drug delivery comprise biocompatibility,
selective aiming of cancer cells, low-cost, and safe process of nanoparticle preparation. In …

Abstract Statement of the Problem: Irinotecan is used as a single agent or in combination
with other drugs to treat metastatic colorectal cancer. However, its usage is largely limited as …

抄録 The interactions between miglitol, an α-glucosidase inhibitor, and six adsorbents
(carbon spheres, cholestyramine, colestimide, sevelamer hydrochloride, calcium …